Enrollment in a large clinical trial evaluating zorevunersen for Dravet syndrome is now expected to be completed in the second quarter of this year, earlier than previously anticipated, positioning the therapy candidate for a potential new drug application (NDA) submission in 2027. That’s according to Stoke Therapeutics, which is…